In a groundbreaking advancement within hepatology, researchers from Hiroshima University and Gifu Kyoritsu University have identified serum levels of Hepatitis B virus RNA (HBV RNA) as a powerful biomarker for predicting the development of hepatocellular carcinoma (HCC) in patients who have been functionally cured of chronic hepatitis B. This discovery promises to redefine clinical surveillance by offering a more precise risk stratification tool than those currently in use, harnessing the molecular intricacies of the virus beyond traditional DNA and antigen measurements.
Chronic hepatitis B remains a major global health burden, afflicting approximately 296 million individuals worldwide. This persistent viral infection is closely linked with an elevated risk of severe liver diseases, notably cirrhosis and hepatocellular carcinoma, which represents the predominant form of primary liver cancer. Though the introduction of nucleoside (nucleotide) analog (NA) therapies has significantly suppressed viral replication and mitigated disease progression, complete elimination of the virus remains elusive due to its unique integration into the host genome.
NA therapy, while effective in reducing serum HBV DNA levels to undetectable thresholds, often results in partial cures characterized by lingering viral antigen presence, with actual functional cures—where both viral DNA and antigens become undetectable—being rarity. Importantly, even in these rare cases, the risk of HCC development cannot be fully eradicated. The persistence of viral genetic material integrated into the host cells represents a continuous oncogenic threat, demanding enhanced methods for early cancer risk prediction.
The investigative team embarked on a retrospective cohort study analyzing 311 patients with chronic hepatitis B who had undergone NA therapy at Ogaki Municipal Hospital between 2000 and 2024. This cohort, predominantly infected with HBV genotype C, exhibited complete suppression of HBV DNA thanks to NA treatment. The researchers meticulously quantified novel serum biomarkers, including HBV core-related antigen (HBcrAg) and HBV RNA, to evaluate their relationship with subsequent HCC onset.
Their findings reveal a striking correlation between detectable levels of serum HBV RNA and an increased future risk of HCC. Among the studied patients, those with quantifiable HBV RNA exhibited a 3.2-fold higher risk of developing HCC independent of conventional clinical risk factors. Notably, HBV RNA demonstrated superior predictive accuracy compared to HBcrAg, a biomarker previously identified for its correlation to viral activity.
This novel insight challenges the existing paradigm, as HBV RNA had been traditionally overlooked since hepatitis B is a DNA virus. The study illustrates that HBV RNA, produced as a transcriptional intermediate during viral replication, serves as a robust indicator of oncogenic risk, potentially reflecting active viral transcriptional cycles undetectable by DNA assays alone. This discovery underscores the complex biology of HBV replication and its oncogenic potential persisting despite viral suppression.
Moreover, the study highlights a particularly vulnerable subgroup — patients exhibiting quantifiable HBV RNA levels combined with compromised liver function, as assessed by the Albumin–Bilirubin (ALBI) grade 2–3. These individuals represent candidates for more frequent and intensive surveillance to preemptively identify HCC, potentially enabling earlier, more effective clinical interventions.
The retrospective design of the research, conducted single-centered with a sample size of 311 patients, warrants additional validation through larger, multicenter cohorts encompassing diverse HBV genotypes to solidify the clinical applicability of HBV RNA as a universal biomarker. The research team has expressed keen interest in national and international collaboration to validate and extend these promising results.
One of the study’s lead authors, Takashi Kumada, emphasizes that although NA medications have revolutionized the clinical management of hepatitis B, the virologic intricacies of HBV integration and persistence necessitate advanced biomarkers like HBV RNA to guide precision medicine. This advancement holds promise not only for enhancing patient prognostication but also for tailoring surveillance protocols to individual risk levels, ultimately advancing therapeutic outcomes.
Beyond its clinical implications, this study sheds light on the fundamental viral biology of HBV, emphasizing transcriptional activity over mere viral presence. The awareness that active viral RNA production signals oncogenic risk even in the face of suppressed DNA levels refines our understanding of HBV’s latent oncogenic mechanisms and challenges researchers to explore therapeutic strategies targeting viral transcription.
The robust methodology included comprehensive collection of clinical data, serial biochemical assays, and cutting-edge molecular quantification techniques to ensure validity. Patients’ serum was analyzed using highly sensitive molecular assays capable of detecting and quantifying HBV RNA, marking a departure from standard clinical practice relying mainly on DNA or antigen quantification.
Collectively, this research adds an essential dimension to the landscape of hepatitis B management by identifying HBV RNA as a predictive biomarker that surpasses established parameters. The implications are far-reaching: better risk stratification may revolutionize long-term follow-up care, reduce morbidity through timely interventions, and ultimately improve survival rates among chronic hepatitis B patients globally.
Supported by Roche Diagnostics Japan, this study represents a vital collaboration between clinical hepatology and molecular virology, promising to accelerate translational research translating molecular biomarkers into actionable clinical tools. The research community and clinical practitioners alike await further developments as multicenter validation studies are planned, heralding a new era in HBV-related cancer prevention.
Subject of Research: People
Article Title: Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression
News Publication Date: 2-Dec-2025
Web References: https://doi.org/10.1111/apt.70483
References: Kumada et al., Alimentary Pharmacology & Therapeutics, December 2, 2025
Image Credits: Kumada et al., Alimentary Pharmacology & Therapeutics, December 2, 2025
Keywords: Hepatitis B virus, HBV RNA, Hepatocellular carcinoma, Chronic hepatitis B, Viral biomarkers, Nucleoside analog therapy, HBcrAg, Liver cancer prediction, Viral suppression, Biomarker validation
